Across an array of neurologic diseases, there is often a lack of objective diagnostic testing. In the case of Parkinson’s disease and related disorders, autopsy studies suggest an over 30% misdiagnosis rate particularly early in the disease course in part because of this lack of easily accessible and reliable diagnostics.
A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders, Christopher Gibbons and Roy Freeman (and other academic colleagues), presented the first-ever data suggesting the possibility that measurable pathological markers in the skin can reveal distinct biological characteristics to help separate one type of synucleinopathy from another.
Clinicians often encounter patients who do not fit neatly into one diagnostic bucket. These cases may present with symptoms of more than one disease, or they may have symptoms
that only partially fulfill diagnostic criteria.
CND Life Sciences is pleased to announce the launch of the Syn-One Clinician Network, a directory of some of the hundreds of neurologists who are using the Syn-One Test® to aid in the diagnosis of Parkinson’s disease and other neurological disorders.
Over 2 million people in the US have a synucleinopathy, and 100,000 are diagnosed every year. Many more patients go undiagnosed because there hasn’t been a simple clinical method available
to make a diagnosis.
A large, population-based study of UK residents demonstrated that a variety of symptoms may be observed in the primary care setting up to a decade before a diagnosis of Parkinson’s disease.
A recent case series report in Movement Disorders examines the potential limitations of dopamine transporter single-photon emission computed tomography (DAT-SPECT) in the diagnosis of Parkinson’s disease, highlighted by cases in which patients with Parkinson’s have scans without evidence of dopaminergic deficit (SWEDDs).
Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.
Al-Qassabi and colleagues recently published a study in Movement Disorders that examined whether 3-mm skin punch biopsies could be used to detect synuclein pathology in patients with REM sleep behavior disorder (RBD).